Maya, a Colorado Public Benefit Corporation (PBC), has developed a measurement-based care platform designed to support psychedelic practitioners and patients.

HaluGen anticipates that this partnership with Maya will drive awareness and potential sales of its genetic test kit, launched in Canada in April and in the U.S. in June.

The test kit identifies specific DNA biomarkers to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.

Timothy Ko, Entheon Biomedical’s CEO, commented on the partnership.

“Maya and Entheon share a mutual vision to help create safer psychedelic experiences and help people make informed choices about their treatment,” he said. “This is also the third such agreement we’ve been able to formalize in as many weeks and is an indicator of the true value that our test brings to the field, including developers such as Maya.”

Maya platform users will be able to fully integrate HaluGen’s test kits to better understand a patient’s genetic profile when preparing for psychedelic-assisted therapies.

“This shared mission to bring psychedelic treatment into the mainstream will be driven by the integration of tools such as these,” said David Champion, Maya founder and CEO, “that create a greater understanding of the potential for these types of treatment.”

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective DMT Products for the purposes of treating addiction and substance use disorders.

Entheon Biomedical Corp. (ENBI) is up 2.63 per cent, trading at $0.39 per share as of 10:38 am ET.